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OBJECTIVEdFactors associated with increasing maternal triglyceride concentrations in late
pregnancy include gestational age, obesity, preeclampsia, and altered glucose metabolism. In a
subgroup of women in the Metformin in Gestational Diabetes (MiG) trial, maternal plasma
triglycerides increased more between enrollment (30 weeks) and 36 weeks in those treated with
metformin compared with insulin. The aim of this study was to explain this ﬁnding by examining
factors potentially related to triglycerides in these women.
RESEARCH DESIGN ANDMETHODSdOf the 733 women randomized to metformin
or insulin in the MiG trial, 432 (219 metformin and 213 insulin) had fasting plasma triglycerides
measured at enrollment and at 36 weeks. Factors associated with maternal triglycerides were
assessed using general linear modeling.
RESULTSdMean plasma triglyceride concentrations were 2.43 (95% CI 2.35–2.51) mmol/L
at enrollment. Triglycerides were higher at 36 weeks in women randomized to metformin (2.94
[2.80–3.08] mmol/L; +23.13% [18.72–27.53%]) than insulin (2.65 [2.54–2.77] mmol/L, P =
0.002; +14.36% [10.91–17.82%], P = 0.002). At 36 weeks, triglycerides were associated with
HbA1c (P = 0.03), ethnicity (P = 0.001), and treatment allocation (P = 0.005). In insulin-treated
women, 36-week triglycerides were associated with 36-week HbA1c (P = 0.02), and in metformin-
treated women, they were related to ethnicity.
CONCLUSIONSdAt 36 weeks, maternal triglycerides were related to glucose control in
women treated with insulin and ethnicity in women treated with metformin. Whether there
are ethnicity-related dietary changes or differences in metformin response that alter the relation-
ship between glucose control and triglycerides requires further study.
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Maternal metabolism in late preg-nancy is catabolic, with increasinginsulin resistance, decreased adi-
pose tissue lipoprotein lipase (LPL) activity,
and increased lipolysis (1). These pro-
cesses combine to ensure the availability
of maternal fuels such as glucose, fatty
acids, and ketone bodies for fetal use (1).
It is recognized that gestational age, ma-
ternal obesity (2), and preeclampsia (3)
are associated with increases in lipids dur-
ing pregnancy. Gestational diabetes mel-
litus (GDM) is also associated with
abnormalities in maternal lipid metabo-
lism (4–6), which may contribute to the
elevated fat mass seen at birth in infants of
women with GDM (7–10).
Maternal glucose control and the
pharmacological therapies used for treat-
ment of GDM have the potential to in-
ﬂuence these changes in maternal lipids
(11). Insulin suppresses adipose tissue li-
polysis and might be expected to reduce
circulating triglycerides (12). Metformin
reduces insulin resistance, but it has also
been suggested to inﬂuence lipid metabo-
lism (13), independent of glycemic control.
In type 2 diabetes, metformin treatment is
associated with a reduction in plasma tri-
glyceride, total cholesterol, LDL cholesterol
(13), and VLDL cholesterol concentrations
(14). Metformin treatment in type 2 diabe-
tes is also associated with increases in LPL
mass level and LDL cholesterol particle size
(15) and with a reduction in the release of
free fatty acids from adipose tissue (16).
We have recently examined maternal
lipids in the Metformin in Gestational
Diabetes (MiG) trial and found that ma-
ternal fasting plasma triglycerides and
measures of glucose control at 36 weeks
were the strongest predictors of custom-
ized birth weight .90th percentile (17).
Interestingly, triglycerides increased
more from randomization to 36 weeks’
gestation in women allocated to metfor-
min than in those allocated to treatment
with insulin, but there was no difference
in customized birth weights or other neo-
natal anthropometry measures between
the groups; there were also no differences
in cord blood triglycerides (17). The aim
of this study was to examine the known
and putative determinants of maternal
triglyceride concentrations and deter-
mine whether the difference seen in ma-
ternal plasma triglycerides at 36 weeks
was due to treatment or other factors
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that may have differed between treatment
groups.
RESEARCH DESIGN AND
METHODSdData were obtained from
the MiG trial dataset (18). This was a pro-
spective, open-label, randomized, con-
trolled trial at multiple sites in New
Zealand and Australia. MiG compared
the use of metformin with insulin treat-
ment for the control of GDM in 733
women diagnosed with GDM, who were
unable to achieve adequate glucose con-
trol after lifestyle intervention. GDM was
diagnosed using standard Australasian
Diabetes in Pregnancy Society criteria
(19). Women were not on either metfor-
min or insulin at enrollment and were
subsequently randomized to primary
pharmacological treatment with one of
these agents. Supplemental insulin was
used as required in the metformin group
to achieve predeﬁned glucose goals, as pre-
viously described (18). The trial was ap-
proved by the institutional review boards
at each participating site, and all subjects
gave written informed consent (18).
A total of 432 participants in the MiG
study with available measurements of
fasting plasma triglycerides at enrollment
and at 36 weeks’ gestation were eligible
for inclusion in the current study (18).
Seventeen women (insulin, n = 8; metfor-
min, n = 9) were excluded from these
analyses as their ethnicity was unclear or
their ethnic category contained,10 indi-
viduals. Inclusion or exclusion of these
women, through assigning them all to
the category of “other ethnicity” did not
change the analyses presented here.
Laboratory analyses
Fasting blood samples were collected
from each woman after an overnight fast
at baseline (20–33 weeks’ gestation) and
at 36 weeks’ gestation. All blood was col-
lected in EDTA and plain tubes and was
sent for processing within 10 min of col-
lection or stored on ice for processing
within 90 min. Aliquots were stored at
2808C for subsequent analysis.
Plasma glucose and triglycerides were
measured by colorimetric enzymatic anal-
ysis on a Hitachi 912 automated meta-
bolic analyzer, using commercially
available kits (Roche Diagnostics GmbH,
Mannheim, Germany). Glycated hemo-
globin (HbA1c) was measured as previ-
ously described, in local laboratories by
methods yielding results that were consis-
tent with those of the Diabetes Control
and Complications Trial (18).
Statistical analysis
Data were analyzed using SPSS (SPSS
Statistics, version 19; IBM, Chicago, IL),
using a = 0.05 (two-sided) to determine
signiﬁcance. The smoking variable
reﬂects a history of smoking during
pregnancy at entry into the study only.
A missing values analysis was un-
dertaken. All variables included had
,10% missing data. For pairwise com-
parisons, missing data were dealt with by
pairwise deletion, and for the regression,
missing data were dealt with by listwise
deletion. Variables showing signiﬁcant
differences at enrollment were analyzed
as percentage change from enrollment to
36 weeks’ gestation rather than the ab-
solute value at 36 weeks. Continuous
variables were described using means
and 95% CIs. When not normally dis-
tributed, data were logarithmically
transformed (log[x]) for analysis, and
geometric means and CIs were reported.
Paired Student t tests were used to
compare triglycerides at enrollment and
36 weeks within treatment groups.
Fisher least signiﬁcant differences test
was used when post hoc analysis was
required. Categorical variables were
summarized using frequencies and per-
centages and analyzed using Pearson x2
test. Univariate and multivariable gen-
eral linear models were used to explore
the associations with maternal triglycer-
ides at enrollment and 36 weeks. At both
time points, triglycerides required log
transformation to provide an appropri-
ately normally distributed outcome vari-
able. Although enrollment triglycerides
were signiﬁcantly correlated with trigly-
cerides at 36 weeks’ gestation in univar-
iate modeling, they were not included in
the multivariate model because of a high
degree of collinearity. The initial multi-
variate models included those variables
that had P, 0.4 in univariate regression.
The model was reﬁned by backward
elimination, reducing the variables in-
cluded to those with P , 0.05. Regres-
sion output is reported as geometric
mean (categorical variables) or geomet-
ric regression coefﬁcient (continuous
variables) and 95% CI as appropriate.
Treatment allocation and outcomes
were examined further to determine the
association of treatment with triglyceride
concentrations, with the regression
model at 36 weeks being stratiﬁed by
treatment allocation (intention to treat).
Regression analysis at 36 weeks’ gesta-
tion was also performed by treatment
received.
RESULTS
Participant characteristics
Of the 733 women in the MiG trial, 432
women (219 metformin and 213 insulin)
were included in this analysis. Of the
women allocated metformin, 97 (44.3%)
were prescribed supplementary insulin.
Women who were excluded because they
had not performed the fasting blood
samples at both time points were heavier
and younger and had higher enrollment
glucose and HbA1c (but not triglycerides)
than those who were included (data not
shown). Additionally, the excluded group
had a higher percentage of Polynesian
women (93 [34.3%] vs. 66 [15.3%]),
fewer Caucasian women (120 [44.3%]
vs. 237 [54.9%]), and lower rates of ter-
tiary education (111 [37.4%] vs. 212
[49.3%]). There were no differences in
the rates of smoking during pregnancy,
diagnosis of preeclampsia, or treatment
allocation. The maternal characteristics
of the women included in this study are
shown in Table 1 and Supplementary
Table 1, and maternal characteristics strat-
iﬁed by treatment received (i.e., met-
formin, metformin and insulin, and
insulin alone) are shown in Supplemen-
tary Table 2. Maternal triglyceride concen-
trations increased from enrollment to
36 weeks while measures of glucose con-
trol improved.
There were no signiﬁcant differences
in enrollment characteristics between the
treatment groups (Table 1). Gestation at
enrollment did not differ signiﬁcantly be-
tween the two groups. At 36 weeks’ ges-
tation, triglyceride concentrations were
higher in the metformin arm (2.94 [95%
CI 2.80–3.08] mmol/L) than the insulin
arm (2.65 [2.54–2.77] mmol/L, P =
0.002). Women treated with metformin
had a higher fasting plasma glucose at
36 weeks (4.38 [4.31–4.46] mmol/L vs.
4.25 [4.17–4.33] mmol/L, P = 0.014) and
gained less weight from enrollment to 36
weeks’ gestation (0.32 [95% CI 20.05 to
0.69] kg vs. 1.63 [1.22–2.04] kg, P ,
0.001) compared with women treated
with insulin. There was no signiﬁcant dif-
ference in plasma HbA1c concentrations,
BMI, systolic blood pressure, or rates of
preeclampsia and smoking between the
two treatment groups at 36 weeks.
Women were also divided into three
groups based on the treatment received:
treatment with metformin alone, met-
formin with insulin, and insulin alone.
There was no signiﬁcant difference in
triglycerides at enrollment. At 36 weeks’
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gestation, plasma triglycerides in these
three groups were signiﬁcantly different
(P = 0.007): metformin alone (2.97 [95%
CI 2.79–3.17] mmol/L), metformin with
insulin (2.90 [2.69–3.12]mmol/L), and in-
sulin alone (2.65 [2.54–2.77]), with a
signiﬁcant mean difference between
both metformin groups and the insulin
group but not between the two groups
receiving metformin. Fasting glucose
and HbA1c were both signiﬁcantly differ-
ent between these three groups at enroll-
ment and at 36 weeks’ gestation, with the
group on metformin with insulin having
higher concentrations than the other two
groups at both time points (Supplementary
Table 2).
Associations with maternal
triglycerides at enrollment
When the data were analyzed overall, by
univariate analysis (Supplementary
Table 3), signiﬁcant associations with
maternal plasma triglyceride concentra-
tions at enrollment were gestational age
(P , 0.001), enrollment HbA1c (P ,
0.001), plasma glucose (P = 0.01), smok-
ing (P = 0.002), and diastolic blood pres-
sure (P = 0.05). Maternal age, weight,
BMI, education, and systolic blood pres-
sure were not signiﬁcantly associated
with the triglyceride level at enrollment.
When data were analyzed using multi-
variate analysis (Table 2), gestational
age, HbA1c at enrollment, ethnicity,
and smoking remained as signiﬁcant
factors.
Associations with maternal
triglycerides at 36 weeks’ gestation
At 36 weeks’ gestation, by univariate anal-
ysis (Supplementary Table 3), factors sig-
niﬁcantly associated with maternal
plasma triglyceride concentrations were
triglycerides at enrollment (P , 0.001),
ethnicity (P = 0.001), and treatment allo-
cation (P = 0.002). Maternal age, duration
of treatment, 36-week BMI, preeclampsia,
measures of 36-week glucose control,
blood pressure, smoking, and educa-
tional status were not signiﬁcantly associ-
ated with maternal plasma triglycerides.
Supplementary Table 4 shows the signif-
icant univariate associations with mater-
nal triglycerides when the analysis was
stratiﬁed by treatment received. By mul-
tivariate analysis of the data overall, eth-
nicity (P = 0.001), treatment allocation
(P = 0.005), and 36-week HbA1c (P =
0.03) remained as signiﬁcant factors.
When the 36-week multivariate anal-
ysis was stratiﬁed by treatment allocation
(Table 3), ethnicity (P = 0.005)was the only
signiﬁcant factor associated with triglycer-
ides inwomen treatedwithmetformin, and
36-week HbA1c (P = 0.02) was the only
signiﬁcant factor associated with triglycer-
ides in women treated with insulin.
When the 36-week multivariate anal-
ysis (Supplementary Table 5) was strati-
ﬁed by treatment received, ethnicity (P =
0.02) remained signiﬁcant for metformin
alone but not for the group receiving both
metformin and insulin or the one receiv-
ing insulin alone. Thirty-six-week HbA1c
was only signiﬁcant for the women receiv-
ing insulin alone (P = 0.02).
Effect of maternal ethnicity
There was a complex relationship between
ethnicity, percent change in triglycerides,
and HbA1c (Fig. 1). At enrollment, there
were no differences in ethnic composition
between themetformin and insulin groups.
Fasting glucose and HbA1c (but not triglyc-
erides) differed between ethnic groups.
The changes seen in maternal triglycerides
Table 1dMaternal characteristics at enrollment and at 36 weeks’ gestation, stratiﬁed by treatment allocation
Variable Metformin Insulin P
Maternal age (years) 33.3 (32.6–34.0) 32.9 (32.2–33.5) 0.42
Caucasian, n (%) 123 (56.2) 114 (53.5) 0.39
Indian, n (%) 27 (12.3) 39 (18.3)
Polynesian, n (%) 35 (16.0) 31 (14.6)
Asian, n (%) 34 (15.5) 29 (13.6)
Smoking during pregnancy, n (%) 40 (18.3) 26 (12.2) 0.08
Tertiary education, n (%) 114 (52.1) 104 (48.8) 0.50
Enrollment measures
Fasting plasma triglycerides (mmol/L) 2.48 (2.36–2.61) 2.37 (2.28–2.48) 0.19
Fasting plasma glucose (mmol/L) 5.12 (5.01–5.24) 5.07 (4.95–5.20) 0.57
HbA1c (%) 5.64 (5.56–5.72) 5.68 (5.59–5.77) 0.46
BMI (kg/m2) 34.5 (33.5–35.5) 33.75 (32.73–34.77) 0.31
Maternal weight (kg) 91.7 (88.6–94.9) 88.93 (85.89–91.98) 0.21
DBP (mmHg) 68.7 (67.5–70.0) 67.6 (66.3–68.8) 0.20
SBP (mmHg) 112.8 (111.0–114.5) 112.3 (110.6–114.0) 0.71
Gestation of enrollment (weeks) 30.1 (29.7–30.6) 30.3 (29.9–30.7) 0.53
36-week gestation measures
Fasting plasma triglycerides (mmol/L) 2.94 (2.80–3.08) 2.65 (2.54–2.77) 0.002
Fasting plasma glucose (mmol/L) 4.38 (4.31–4.46) 4.25 (4.17–4.33) 0.014
HbA1c (%) 5.59 (5.52–5.66) 5.62 (5.54–5.71) 0.50
BMI (kg/m2) 34.48 (33.41–35.55) 33.92 (32.89–34.95) 0.46
Maternal weight (kg) 91.89 (88.59–95.20) 89.36 (86.25–92.46) 0.27
Change in weight from enrollment (kg) 0.32 (20.05 to 0.69) 1.63 (1.22–2.04) ,0.001
DBP (mmHg) 71.9 (70.6–73.2) 69.3 (68.0–70.6) ,0.01
SBP (mmHg) 116.4 (114.5–118.4) 114.3 (112.6–116.0) 0.71
Preeclampsia, n (%) 11 (5.0) 11 (5.2) 0.95
Data are presented as mean (95% CI) except where indicated. DBP, diastolic blood pressure; SBP, systolic blood pressure.
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and HbA1c between enrollment and 36
weeks were related to both treatment and
ethnicity (Fig. 1A and B). With insulin
treatment, there was no difference in per-
cent change in triglycerides between eth-
nicities.
Effect of maternal smoking
Women who smoked during pregnancy
had higher enrollment triglyceride con-
centrations (smoking, 2.75 [95% CI
2.51–3.02] mmol/L; nonsmoking, 2.37
[2.29–2.46] mmol/L; P = 0.002), but
this difference was not signiﬁcant at 36
weeks (smoking, 2.91 [2.67–3.17]
mmol/L; nonsmoking, 2.78 [2.68–2.87]
mmol/L; P = 0.30). The rates of smoking
during pregnancy did not differ between
ethnicities or by treatment allocation
(data not shown).
CONCLUSIONSdIn this group of
women with GDM, who required medi-
cation for glucose control at a mean of 30
weeks’ gestation, maternal plasma triglyc-
erides at enrollment were associated with
gestational age, measures of glucose con-
trol, ethnicity, and smoking. At 36 weeks’
gestation, maternal triglyceride concen-
tration was associated with ethnicity, glu-
cose control, and treatment allocation. In
women whose GDM was managed with
insulin, 36-week triglycerides were most
strongly associated with measures of glu-
cose control, whereas in women whose
GDM was managed with metformin, 36-
week triglycerides were most strongly as-
sociated with ethnicity.
We found that plasma triglyceride
concentrations in women treated withmet-
formin were higher than in those treated
with insulin at 36 weeks’ gestation. The
plasma triglyceride concentrations found
in this study irrespective of the treatment
arm are similar to or lower than those re-
ported in women with treated GDM (2–
3.0 mmol/L, managed with diet or insulin
therapy) during the late second (8–10,20)
and late third trimester (8,20,21). They
are also similar to the concentrations re-
ported in normal pregnancy in the third
trimester (;2–2.8 mmol/L) (20,22,23).
Since elevated glucose concentrations are
associated with increased triglyceride con-
centrations, the triglyceride concentra-
tions in this study suggest that the level
of glucose control achievedwith treatment
in the women in this study may have
exerted a beneﬁcial effect on triglyceride
elevations.
The fasting plasma glucose assessed
concomitant with plasma triglycerides at
36 weeks was higher in the metformin
treatment group than the insulin treatment
group. In the multivariate analysis, how-
ever, plasma glucose did not predict tri-
glyceride concentrations. Therefore, the
higher fasting plasma glucose does not
provide an explanation as to why triglyc-
eride concentrations were higher in the
metformin-treated women. Additionally,
other factors known to increase triglycer-
ide concentrations, namely obesity (2),
smoking, and preeclampsia (3), were also
similar between treatment arms. Metfor-
min improves insulin resistance, and it
has been suggested that it inﬂuences lipids
directly. Insulin can directly affect adipose
tissue by reducing lipolysis and increasing
LPL activity (24), which could explain the
lower triglycerides in the insulin arm com-
pared with the metformin arm.
The subtle differences in plasma tri-
glyceride levels between women allocated
metformin and those allocated insulin
could contribute to differences in overall
fetal nutrition along a continuum of lipid
exposure, as previously described for
glucose exposure in the Hyperglycemia
and Adverse Pregnancy Outcomes study
(25). Elevated maternal triglycerides have
been associated with multiple adverse
outcomes for the mother and infant.
However, no interventional trials directed
at lowering maternal triglycerides have
been reported. If it was demonstrated
that lowering maternal triglycerides pro-
vides beneﬁcial pregnancy outcomes,
then the ﬁnding that metformin is associ-
ated with higher maternal triglycerides
compared with insulin at 36 weeks’ ges-
tation may alter the choice of pharmaco-
therapy for women with GDM.
Table 2dAssociations with maternal triglycerides at enrollment, in multivariate analysis
Parameter
Geometric mean or
regression coefﬁcient*
95% CI
PLower bound Upper bound
Gestation of enrollment (weeks) 1.02 1.01 1.03 ,0.001
Ethnicity 0.04
Asian 2.74 2.50 3.00
Polynesian 2.32 2.12 2.54
Indian 2.56 2.34 2.80
Caucasian 2.59 2.46 2.73
Smoking during pregnancy 2.73 2.50 2.97 ,0.01
No smoking 2.38 2.29 2.48
Enrollment HbA1c 1.15 1.09 1.21 ,0.001
*The data represent geometric mean and 95%CI for categorical variables and geometric regression coefﬁcient
and 95% CI for continuous variables.
Table 3dAssociations with maternal triglycerides at 36 weeks’ gestation, in multivariate
analysis, stratiﬁed by treatment allocation
Geometric mean or
regression coefﬁcient*
95% CI
PLower bound Upper bound
Insulin
Ethnicity 0.14
Asian 2.96 2.63 3.33
Polynesian 2.43 2.15 2.74
Indian 2.69 2.43 2.98
Caucasian 2.64 2.48 2.81
36-week HbA1c 1.10 1.02 1.18 0.02
Metformin
Ethnicity ,0.01
Asian 3.34 2.96 3.77
Polynesian 2.48 2.19 2.80
Indian 2.70 2.35 3.10
Caucasian 3.00 2.81 3.20
36-week HbA1c 1.04 0.94 1.16 0.46
*The data represent geometric mean and 95%CI for categorical variables and geometric regression coefﬁcient
and 95% CI for continuous variables.
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These analyses showed ethnic differ-
ences in the change in triglyceride levels
in women on metformin but not in
women on insulin. Maternal triglycerides
at enrollment did not differ between
ethnicities. The examination of ethnicity
in the current analyses is a post hoc
subgroup analysis and thus needs to be
treated with caution. However, ethnic
differences in the relationship between
insulin resistance, body adipose stores
(26), lipids (27,28), and adipokines
(29,30) have been reported before, and
ethnic differences in lipid and lipoprotein
metabolism have also been described in
pregnancy (31,32). It is also possible
that there are ethnic variations in the me-
tabolism of or pharmacological response
to metformin (33–35). Alternatively, the
ﬁndings of the current analyses may be
due to systematic ethnic differences in
diet or glucose and lipid metabolism
and require conﬁrmation and further ex-
ploration in future studies.
The strength of these analyses is that
the data were collected as part of a pro-
spective, randomized, controlled trial.
Limitations include the use of a subgroup
of women from the original trial who are
different from those who were not in-
cluded. Women who did not have blood
tests taken at both time points could not
be included in this study, and unsurpris-
ingly, these women belong to a lower
socioeconomic group. Another potential
weakness is that the smoking status in
women was documented at enrollment
but not at 36 weeks, so there is a possi-
bility that the rates at which women
ceased or commenced smoking within
the time frame of the study differed
between the treatment groups. Given
that this was a randomized trial, if that
were true, we would have to propose that
insulin ormetformin had a direct effect on
smoking behavior, which we consider
unlikely. More detailed and consistent
smoking status information would be
important to document in future studies.
The other weakness of this study is a
reduced number of observations in the
subgroup analyses, increasing the chance
for error. With this in mind, the analyses
of ethnic differences, while intriguing,
require conﬁrmation in future studies.
In particular, the issue of maternal diet
requires further exploration. The exami-
nation of dietary information could ac-
count for the apparent differences in the
relationship between ethnicity and treat-
ment seen in this study. Although the
details of the diet the women in this study
were asked to follow are known, their
actual diet is not. There may have been
differences in diet related to the treat-
ment, which would also account for less
weight gain in women treated with met-
formin. Insulin is frequently associated
with increased appetite (36), and women
treated with insulin may not have re-
stricted their dietary intake to the same
degree as women taking metformin,
who might have been trying to avoid sup-
plemental insulin. Women taking insulin
would have been able to increase their
dose of insulin to maintain glucose con-
trol, despite eating more. Restrictions to
dietary intake in women taking metfor-
min, leading to prolonged fasting by the
time of the morning blood sample could
have produced increased maternal
plasma triglycerides (37). This has not
been reported in the setting of a hypo-
caloric diet in obese women with GDM
(38), but increased free fatty acids and a
trend to increasedmaternal fasting triglyc-
erides have been reported with the short-
term use of a low-carbohydrate diet in
women with GDM (39). Future studies
examining the impact of metformin and
insulin on triglycerides should include
detailed dietary assessment to adequately
examine this issue.
In this cohort of metformin- and
insulin-treated women in a randomized
trial of women with GDM, maternal
plasma triglyceride concentrations at 36
weeks were higher during treatment with
metformin than treatment with insulin,
despite a lower weight gain in women
treated with metformin. The differences
noted in triglyceride levels between treat-
ments were small, and maternal triglyc-
eride levels were within the reported
normal range for pregnancy. Although
fasting glucose measured at the same time
was higher in women treated with met-
formin, this did not explain the difference
in triglycerides. Glucose control was an
important factor in triglyceride levels in
women treated with insulin, whereas
ethnicity was an important factor in
women treated with metformin. These
data demonstrate that we have an incom-
plete understanding about treating GDM
and the interactions between glucose,
lipids, diet, medication, and ethnicity.
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